STOCKSURGICAL & MEDICAL INSTRUMENTS & APPARATUSUpdated 2026-08-16
Here’s whether DexCom, Inc. (DXCM) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.08% over 10 days); strong 1-year return of +12.2%; 3-month momentum positive (+45.6%). Concerns: RSI 77 — overbought, elevated pullback risk. Currently 2.4% off its 52-week high. Score: +5/7.
DXCM is in a confirmed uptrend, trading above both its 50-day ($76.11) and 200-day ($68.69) moving averages. With an RSI of 77.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +12.2% compares to +20.4% for SPY (trailed the market by 8.1%).
$10,000 invested 1 year ago→ $11,224 today
vs. S&P 500 (SPY) — same period trailed market by 8.1%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($68.69)
✓Above 50-day MA ($76.11)
!RSI(14) neutral zone (30–70) — currently 77.0
✓Positive return (+12.2%)
✓Within 10% of period high (−2.4%)
Period Range $89.75
$54.11$91.96
RSI (14) 77.0
0 · OversoldOverbought · 100
Key Metrics
Price$89.75
Period Return+12.2%
Period High$91.96
Period Low$54.11
Drawdown−2.4%
MA-50$76.11
MA-200$68.69
RSI (14)77.0
Avg Volume (30d)5.2M
vs. SPYtrailed by 8.1%
Return Rank#552 of 1252
Trend Signals
Price is above the 200-day moving average ($68.69)